Reutens AT, Jandeleit-Dahm K, Thomas M et al (2020) A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: protocol and statistical considerations
Given the critical role of weight loss in MASLD management, pharmacologic agents that induce weight loss are being investigated as potential therapies
When does the clock start
By doing so, in atherosclerotic plaques from murine aortas, GLP-1RAs regulate proinflammatory mediators and the phenotype of immune cells
New GLP-1 Clinical Study Finds Calocurb Reduces Body Weight and Body Fat Without Loss of Muscle Mass The natural GLP-1 activator is clinically shown to support fat loss, including visceral fat reduction, while preserving lean muscle AUCKLAND, New Zealand, July 23, 2026 --(BUSINESS WIRE)--Calocurb, the New Zealand-based company bringing the world the first 100% natural GLP-1 activator, announces today the publication of a new clinical study in US medical journal, Obesity Pillars, demonstrating Calocurb's effectiveness in weight loss and muscle preservation
Think of it as light version GLP-1 usethough, again, not an official recommendation